EU sets early Oct. deadline for Eli Lilly's $5.4B bid for Novartis

European Union regulators have set an Oct. 3 deadline for approving or denying Eli Lilly's ($LLY) $5.4 billion bid for the animal health business of Switzerland's Novartis ($NVS). Eli Lilly agreed to buy the unit in April. If approved, the combined company would create the second-biggest animal health company in the world. According to the EU's antitrust authority, the deal was sent to the European Commission last week. Report | More

Suggested Articles

On New Year’s Day, Sanofi and Boehringer Ingelheim closed a $12.5 billion asset swap that had been in the works for a year, giving the closely held Germany-…

One of the priorities at France’s Ceva Santé Animale is to boost the company’s presence in the rapidly growing market for vaccines to prevent emerging diseases…

Jaguar Animal Health never caught fire on Wall Street after being spun out of Napo Pharmaceuticals in 2015. Its founders hope merging the company with its…